However, a clear trend was demonstrated towards improvement in overall survival.
News
AbbVie to buy Allergan in $63b mega-merger
The deal is the second huge merger this year, after January’s Bristol-Myers Squibb & Celgene deal.
FDA Priority Review granted for GSK’s Zejula
There are around 7,500 new ovarian cancer cases in the UK every year.
NHS to open young people’s gambling addiction service
The news comes after a recent Gambling Comission report found 55,000 children are classed as having a gambling problem.
Recent Ozempic, Victoza data ‘promising’ for diabetic kidney disease
Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk talks exclusively to PharmaTimes.
EMA validates Santhera’s Puldysa MAA
Santhera expects an opinion by the CHMP around mid 2020.
Kymab, LifeArc form medicines discovery alliance
The partnership provides LifeArc with access to Kymab’s suite of antibody discovery technologies, including Darwin.
The 2019 Sales Awards introduces a brand new category for sales managers
The 2019 PharmaTimes Sales Awards have been re-vamped with the inclusion of a brand new category – The Sales Manager of the Year.
Sanofi, Regeneron successful in phase II asthma trial
The investigational IL-33 antibody REGN3500 met its primary and secondary endpoints in the joint phase II proof-of-concept trial.
FDA expansion for Symdeko in cystic fibrosis
The indication is now for pediatric patients ages six years and older with certain genetic mutations.
Government pledges to fight ‘deadly’ antimicrobial resistance
A total of £32 million has been committed to accelerate the UK’s work in the global fight against AMR.
Talzenna bags EU approval for gBRCA-mutated breast cancer
The indication is for patients with inherited BRCA-mutated locally advanced or metatastatic breast cancer.
MHRA renews EAMS scientific opinion for Puldysa in DMD
The drug has been available in the UK through EAMS since June 2017.
Boosting natural repair could help solve age related macular degeneration
Fight for Sight has announced funding for scientists at Queen’s University Belfast.
£8m drug-resistance grant for Oxford Drug Design
Drug-resistant superbugs are on the rise worldwide and represent a threat to global public health and health security.
